Same Drug Class

Osimertinib vs Rituximab

Osimertinib vs Rituximab: Overview

This comparison examines the pharmacological differences between Osimertinib and Rituximab.

Mechanism of Action

Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics

Half-life: Osimertinib — 48 hours; Rituximab — 22 days.

Chemical Properties

Molecular Formula: Osimertinib — C28H33N7O2.

Molecular Weight: Osimertinib — 499.6050 g/mol.

Type: Osimertinib — Small molecule; Rituximab — Antibody.